Through these extracellular vesicles, CircZFR can be transferred to HCC cells, where it inhibits the signal transducer and activator of transcription 3 (STAT3)/nuclear factor kappa B (NF-kβ) signaling pathway, ultimately promoting HCC progression and chemotherapy resistance (Zhou et al., 2022). This evidence concerns the gene STAT3 and hepatocellular carcinoma.